Colistimethate Sodium/Colistin Sulfomethate Sodium
Indication
Non-Cystic Fibrosis Bronchiectasis
Amber level 0
Brand:
Colomycin®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Infection
Background
Colistimethate sodium (Colomycin®) is recommended as an option for patients with non-cystic fibrosis bronchiectasis, colonised with Pseudomonas aeruginosa who have three or more exacerbations per year requiring antibiotics or fewer exacerbations that are causing significant morbidity, in whom long term nebulised antibiotic therapy is being considered.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for initiation in primary care
Supporting documents: